Related references
Note: Only part of the references are listed.Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers
Caihong Zhu et al.
BIOMATERIALS (2010)
Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles
Ashlynn L. Z. Lee et al.
BIOMATERIALS (2009)
Protamine sulfate/poly(L-aspartic acid) polyionic complexes self-assembled via electrostatic attractions for combined delivery of drug and gene
Han Cheng et al.
BIOMATERIALS (2009)
Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Constantijne H. Mom et al.
CLINICAL CANCER RESEARCH (2009)
Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum
Lavanya Y. Peddada et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery
Hemin Nie et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Inhibition of vimentin or β1 integrin revert morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo
Xueping Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Old polymer learns new tracts
Michael J. Campolongo et al.
NATURE MATERIALS (2009)
CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP
Renata Zobalova et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Efficient intracellular delivery of functional proteins using cationic polymer core/shell nanoparticles
Ashlynn L. Z. Lee et al.
BIOMATERIALS (2008)
Therapeutic nanoparticles for drug delivery in cancer
Kwangjae Cho et al.
CLINICAL CANCER RESEARCH (2008)
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Ricky W. Johnstone et al.
NATURE REVIEWS CANCER (2008)
Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis
Susan L. Kohlhaas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Colorectal cancer: a model for epigenetic tumorigenesis
J. J. L. Wong et al.
GUT (2007)
Multifunctional nanocarriers
Vladimir P. Torchilin
ADVANCED DRUG DELIVERY REVIEWS (2006)
Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer
Yong Wang et al.
NATURE MATERIALS (2006)
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Rajni Sinha et al.
MOLECULAR CANCER THERAPEUTICS (2006)
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas
Mathilde Jalving et al.
CLINICAL CANCER RESEARCH (2006)
Clonogenic assay of cells in vitro
Nicolaas A. P. Franken et al.
NATURE PROTOCOLS (2006)
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
LD Zhang et al.
CANCER GENE THERAPY (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis
ZY Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy
CMM Van Geelen et al.
DRUG RESISTANCE UPDATES (2004)
Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms
HB Zhu et al.
MOLECULAR THERAPY (2004)
TRAIL and apoptosis induction by TNF-family death receptors
SL Wang et al.
ONCOGENE (2003)
The dawning era of polymer therapeutics
R Duncan
NATURE REVIEWS DRUG DISCOVERY (2003)
Didox (A novel ribonucleotide reductase inhibitor) overcomes bcl-2 mediated radiation resistance in prostate cancer cell line PC-3
MS Inayat et al.
CANCER BIOLOGY & THERAPY (2002)
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL
C Voelkel-Johnson et al.
CANCER GENE THERAPY (2002)
TRAIL and its receptors in the colonic epithelium: A putative role in the defense of viral infections
J Strater et al.
GASTROENTEROLOGY (2002)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
Death receptor ligands, in particular TRAIL, to overcome drug resistance
S de Jong et al.
CANCER AND METASTASIS REVIEWS (2001)
Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
XD Zhang et al.
JOURNAL OF IMMUNOLOGY (2000)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
Doxorubicin-loaded poly(ethylene glycol)-poly(β-benzyl-l-aspartate) copolymer micelles:: their pharmaceutical characteristics and biological significance
K Kataoka et al.
JOURNAL OF CONTROLLED RELEASE (2000)
Share Paper
